Quantcast

Latest Access Pharmaceuticals Inc. Stories

2010-06-28 07:30:00

DALLAS and NEW YORK, June 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) President and CEO Jeffrey B. Davis will present at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET. The conference is being held at the Roosevelt Hotel in New York City. Davis will provide an overview of Access' clinical development programs and update investors on commercialization launch activities for its lead product, MuGard -...

2010-06-24 07:30:00

DALLAS and NEW YORK, June 24 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical...

2010-06-22 07:30:00

DALLAS and NEW YORK, June 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is sponsoring an Oral Mucositis Symposium today for researchers and health care professionals attending the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. later this week. In an effort to further educate and build awareness of the debilitating side...

2010-06-15 07:30:00

DALLAS and NEW YORK, June 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has initiated a broad-scale MuGard Centers-of-Excellence Sampling Program with leading oncology networks for its lead product, MuGard, a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. (Photo:...

2010-06-10 07:30:00

DALLAS, June 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Senior VP of R&D, David Nowotnik, Ph.D., will give two presentations today on the Company's Cobalamin siRNA program at the Novel Nanodelivery of siRNA and miRNA Symposium, hosted by the California NanoSystems Institute (CNSI) of UCLA. Access Pharma's invited oral presentation and its...

2010-05-19 14:02:00

DALLAS and NEW YORK, May 19 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research initiated coverage on the Company with an "Outperform" and a 12-month price target of $8.00. The report can be viewed by clicking on following link: http://www.accesspharma.com/downloads/analyst-reports/ACCPInitiation.pdf About Zacks: Founded in...

2010-04-21 07:30:00

DALLAS and NEW YORK, April 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis,...

2010-04-19 07:30:00

DALLAS and NEW YORK, April 19 /PRNewswire-FirstCall/ -- Jeffrey Davis, President and CEO of ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, was recently interviewed by the Proactive Investors Group, an international financial media company. In the interview, Davis provides an overview of Access Pharma's robust product pipeline, an update on the global rollout of its FDA-approved product MuGard,...

2010-04-15 07:30:00

DALLAS and NEW YORK, April 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis ("OM"), Stephen T. Sonis, DMD, DMSc, Chief of the Division of Oral Medicine at the Dana Farber Cancer Institute and Program Director for Supportive Cancer Care at Clinical Assistance Programs, LLC ("CAP"), to further...

2010-04-13 07:30:00

DALLAS and NEW YORK, April 13 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it has completed its first commercial scale production run of MuGard in North America at Accupac, Inc. manufacturing facilities outside Philadelphia. Access intends to use the initial batches of MuGard for pre-launch key institution evaluations, preliminary stock for select wholesalers and specialty distributors, and additional post-approval studies to be conducted...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.